Laurence M. Harewood

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Early Results from the CONFIRM Trial: Utility of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Active Surveillance for Prostate Cancer.

Early Results from the CONFIRM Trial: Utility of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Active Surveillance for Prostate Cancer.

Journal: European urology oncology

Published: November 17, 2024

The CONFIRM trial protocol: the utility of prostate-specific membrane antigen positron emission tomography/computed tomography in active surveillance for prostate cancer.

The CONFIRM trial protocol: the utility of prostate-specific membrane antigen positron emission tomography/computed tomography in active surveillance for prostate cancer.

Journal: BJU international

Published: October 31, 2023

The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology.

The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology.

Journal: Nature communications

Published: February 15, 2021

Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival.

Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 03, 2020

Use of prostate-specific membrane antigen positron-emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer.

Use of prostate-specific membrane antigen positron-emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer.

Journal: BJU international

Published: June 25, 2020

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.

Journal: European urology

Published: March 01, 2018

Multiparametric magnetic resonance imaging for prostate cancer-a comparative study including radical prostatectomy specimens.

Multiparametric magnetic resonance imaging for prostate cancer-a comparative study including radical prostatectomy specimens.

Journal: World journal of urology

Published: July 13, 2016

Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression.

Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression.

Journal: Oncotarget

Published: October 18, 2015

Does perineural invasion in a radical prostatectomy specimen predict biochemical recurrence in men with prostate cancer?

Does perineural invasion in a radical prostatectomy specimen predict biochemical recurrence in men with prostate cancer?

Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Published: June 02, 2015

Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer.

Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer.

Journal: BJU international

Published: January 29, 2013

Re-evaluating the biological significance of seminal vesicle invasion (SVI) in locally advanced prostate cancer.

Re-evaluating the biological significance of seminal vesicle invasion (SVI) in locally advanced prostate cancer.

Journal: BJU international

Published: December 01, 2012

Utility of RhoC and ZAG protein expression as biomarkers for prediction of PSA failure following radical prostatectomy for high grade prostate cancer.

Utility of RhoC and ZAG protein expression as biomarkers for prediction of PSA failure following radical prostatectomy for high grade prostate cancer.

Journal: Pathology

Published: September 01, 2012

Showing 1-12 of 15

Last Updated: 09/26/2026